Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

124 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A multi-centre longitudinal study analysing multiple sclerosis disease-modifying therapy prescribing patterns during the COVID-19 pandemic.
Lal AP, Foong YC, Sanfilippo PG, Spelman T, Rath L, Levitz D, Fabis-Pedrini M, Foschi M, Habek M, Kalincik T, Roos I, Lechner-Scott J, John N, Soysal A, D'Amico E, Gouider R, Mrabet S, Gross-Paju K, Cárdenas-Robledo S, Moghadasi AN, Sa MJ, Gray O, Oh J, Reddel S, Ramanathan S, Al-Harbi T, Altintas A, Hardy TA, Ozakbas S, Alroughani R, Kermode AG, Surcinelli A, Laureys G, Eichau S, Prat A, Girard M, Duquette P, Hodgkinson S, Ramo-Tello C, Maimone D, McCombe P, Spitaleri D, Sanchez-Menoyo JL, Yetkin MF, Baghbanian SM, Karabudak R, Al-Asmi A, Jakob GB, Khoury SJ, Etemadifar M, van Pesch V, Buzzard K, Taylor B, Butzkueven H, Van der Walt A. Lal AP, et al. Among authors: maimone d. J Neurol. 2024 Sep;271(9):5813-5824. doi: 10.1007/s00415-024-12518-7. Epub 2024 Jun 27. J Neurol. 2024. PMID: 38935148 Free PMC article.
Comparative Effectiveness of Autologous Hematopoietic Stem Cell Transplant vs Fingolimod, Natalizumab, and Ocrelizumab in Highly Active Relapsing-Remitting Multiple Sclerosis.
Kalincik T, Sharmin S, Roos I, Freedman MS, Atkins H, Burman J, Massey J, Sutton I, Withers B, Macdonell R, Grigg A, Torkildsen Ø, Bo L, Lehmann AK, Havrdova EK, Krasulova E, Trnený M, Kozak T, van der Walt A, Butzkueven H, McCombe P, Skibina O, Lechner-Scott J, Willekens B, Cartechini E, Ozakbas S, Alroughani R, Kuhle J, Patti F, Duquette P, Lugaresi A, Khoury SJ, Slee M, Turkoglu R, Hodgkinson S, John N, Maimone D, Sa MJ, van Pesch V, Gerlach O, Laureys G, Van Hijfte L, Karabudak R, Spitaleri D, Csepany T, Gouider R, Castillo-Triviño T, Taylor B, Sharrack B, Snowden JA; MSBase Study Group Collaborators; MSBase Study Group Authors; Mrabet S, Garber J, Sanchez-Menoyo JL, Aguera-Morales E, Blanco Y, Al-Asmi A, Weinstock-Guttman B, Fragoso Y, de Gans K, Kermode A; MSBase Study Group. Kalincik T, et al. Among authors: maimone d. JAMA Neurol. 2023 Jul 1;80(7):702-713. doi: 10.1001/jamaneurol.2023.1184. JAMA Neurol. 2023. PMID: 37437240 Free PMC article.
Effectiveness of cladribine compared to fingolimod, natalizumab, ocrelizumab and alemtuzumab in relapsing-remitting multiple sclerosis.
Roos I, Sharmin S, Malpas C, Ozakbas S, Lechner-Scott J, Hodgkinson S, Alroughani R, Eichau Madueño S, Boz C, van der Walt A, Butzkueven H, Buzzard K, Skibina O, Foschi M, Grand'Maison F, John N, Grammond P, Terzi M, Prévost J, Barnett M, Laureys G, Van Hijfte L, Luis Sanchez-Menoyo J, Blanco Y, Oh J, McCombe P, Ramo Tello C, Soysal A, Prat A, Duquette P, Yamout BI, Khoury S, van Pesch V, Macdonell R, José Sá M, Slee M, Kuhle J, Maimone D, Spitaleri D, Willekens B, Asmi AA, Tallantyre E, Robertson NP, Coles A, L Brown JW, Kalincik T. Roos I, et al. Among authors: maimone d. Mult Scler. 2024 Aug;30(9):1163-1175. doi: 10.1177/13524585241267211. Epub 2024 Aug 1. Mult Scler. 2024. PMID: 39087208
Predicted Expenditure for Prescription Drugs for Multiple Sclerosis in the Italian Market Between 2023 and 2028: Results of the Oracle Project.
Paolicelli D, Borriello G, Clerici R, Colombo E, Croce D, D'Amico E, De Rossi N, Di Sapio A, Fenu G, Maimone D, Marfia GA, Moccia M, Perini P, Piscaglia MG, Razzolini L, Riccaboni M, Signoriello E, Agostoni G, Farina A, Mondino M, Berruto F, Tettamanti A, Donnaloja F, Tortorella C. Paolicelli D, et al. Among authors: maimone d. Neurol Ther. 2024 Oct;13(5):1415-1430. doi: 10.1007/s40120-024-00644-3. Epub 2024 Aug 2. Neurol Ther. 2024. PMID: 39093539 Free PMC article.
Disease Activity in Pregnant and Postpartum Women With Multiple Sclerosis Receiving Ocrelizumab or Other Disease-Modifying Therapies.
Yeh WZ, Van Der Walt A, Skibina OG, Kalincik T, Alroughani R, Kermode AG, Fabis-Pedrini MJ, Carroll WM, Lechner-Scott J, Boz C, Ozakbas S, Buzzard K, Habek M, John NA, Prat A, Girard M, Duquette P, Baghbanian SM, Hodgkinson S, Van Pesch V, Laureys G, Willekens B, Prevost J, Foschi M, De Gans K, Horakova D, Havrdova EK, Karabudak R, Patti F, Mccombe PA, Maimone D, Altintas A, Ampapa R, Spitaleri D, Gerlach OHH, Sa MJ, Hughes S, Gouider R, Mrabet S, Macdonell RA, Turkoglu R, Cartechini E, Al-Asmi A, Soysal A, Oh J, Muros-Le Rouzic E, Guye S, Pasquarelli N, Butzkueven H, Jokubaitis VG; MSBase Study Group. Yeh WZ, et al. Among authors: maimone d. Neurol Neuroimmunol Neuroinflamm. 2024 Nov;11(6):e200328. doi: 10.1212/NXI.0000000000200328. Epub 2024 Oct 23. Neurol Neuroimmunol Neuroinflamm. 2024. PMID: 39442037 Free PMC article.
Boosting multiple sclerosis lesion segmentation through attention mechanism.
Rondinella A, Crispino E, Guarnera F, Giudice O, Ortis A, Russo G, Di Lorenzo C, Maimone D, Pappalardo F, Battiato S. Rondinella A, et al. Among authors: maimone d. Comput Biol Med. 2023 Jul;161:107021. doi: 10.1016/j.compbiomed.2023.107021. Epub 2023 May 10. Comput Biol Med. 2023. PMID: 37216775 Free article.
Effectiveness of Disease-Modifying Treatment on Spinal Cord Lesion Formation in Relapse-Onset Multiple Sclerosis: An MSBase Registry Study.
Kreiter D, Kalincik T, Hupperts R, Patti F, Spitaleri D, Foschi M, Surcinelli A, Maimone D, Yamout B, Khoury SJ, Lechner-Scott J, Ozakbas S, Gerlach O; MSBase Study Group. Kreiter D, et al. Among authors: maimone d. CNS Drugs. 2024 Nov;38(11):921-930. doi: 10.1007/s40263-024-01115-x. Epub 2024 Sep 6. CNS Drugs. 2024. PMID: 39242483 Free PMC article.
Correction to: Progression independent of relapse activity in relapsing multiple sclerosis: impact and relationship with secondary progression.
Portaccio E, Betti M, De Meo E, Addazio I, Pastò L, Razzolini L, Totaro R, Spitaleri D, Lugaresi A, Cocco E, Onofrj M, Di Palma F, Patti F, Maimone D, Valentino P, Clerici VT, Protti A, Ferraro D, Lus G, Maniscalco GT, Morra VB, Salemi G, Granella F, Pesci I, Bergamaschi R, Aguglia U, Vianello M, Simone M, Lepore V, Iaffaldano P, Comi G, Filippi M, Trojano M, Amato MP; Italian Multiple Sclerosis Register. Portaccio E, et al. Among authors: maimone d. J Neurol. 2024 Oct;271(10):7066-7068. doi: 10.1007/s00415-024-12627-3. J Neurol. 2024. PMID: 39231861 Free PMC article. No abstract available.
124 results